Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 125

Similar articles for PubMed (Select 22736099)

1.

Pretreatment synovial transcriptional profile is associated with early and late clinical response in rheumatoid arthritis patients treated with rituximab.

Hogan VE, Holweg CT, Choy DF, Kummerfeld SK, Hackney JA, Teng YK, Townsend MJ, van Laar JM.

Ann Rheum Dis. 2012 Nov;71(11):1888-94. doi: 10.1136/annrheumdis-2011-201115. Epub 2012 Jun 26.

PMID:
22736099
2.

Identification of candidate genes for rituximab response in rheumatoid arthritis patients by microarray expression profiling in blood cells.

Julià A, Barceló M, Erra A, Palacio C, Marsal S.

Pharmacogenomics. 2009 Oct;10(10):1697-708. doi: 10.2217/pgs.09.99.

PMID:
19842941
3.

Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy.

Das S, Vital EM, Horton S, Bryer D, El-Sherbiny Y, Rawstron AC, Ponchel F, Emery P, Buch MH.

Ann Rheum Dis. 2014 May;73(5):909-12. doi: 10.1136/annrheumdis-2013-204417. Epub 2014 Jan 2.

PMID:
24385201
4.

Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis.

Badot V, Galant C, Nzeusseu Toukap A, Theate I, Maudoux AL, Van den Eynde BJ, Durez P, Houssiau FA, Lauwerys BR.

Arthritis Res Ther. 2009;11(2):R57. doi: 10.1186/ar2678. Epub 2009 Apr 23.

5.

The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients.

Raterman HG, Vosslamber S, de Ridder S, Nurmohamed MT, Lems WF, Boers M, van de Wiel M, Dijkmans BA, Verweij CL, Voskuyl AE.

Arthritis Res Ther. 2012 Apr 27;14(2):R95. doi: 10.1186/ar3819.

6.

Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.

van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Rustenburg F, Baggen JM, Verweij CL, Tak PP.

Ann Rheum Dis. 2008 Apr;67(4):563-6. Epub 2007 Nov 27.

PMID:
18042642
7.

Synovial tissue rank ligand expression and radiographic progression in rheumatoid arthritis: observations from a proof-of-concept randomized clinical trial of cytokine blockade.

Rooney T, Edwards CK 3rd, Gogarty M, Greenan L, Veale DJ, FitzGerald O, Dayer JM, Bresnihan B.

Rheumatol Int. 2010 Nov;30(12):1571-80. doi: 10.1007/s00296-009-1191-1. Epub 2009 Oct 22.

PMID:
19847430
8.

Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis.

Vos K, Thurlings RM, Wijbrandts CA, van Schaardenburg D, Gerlag DM, Tak PP.

Arthritis Rheum. 2007 Mar;56(3):772-8.

9.

Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients.

Thurlings RM, Boumans M, Tekstra J, van Roon JA, Vos K, van Westing DM, van Baarsen LG, Bos C, Kirou KA, Gerlag DM, Crow MK, Bijlsma JW, Verweij CL, Tak PP.

Arthritis Rheum. 2010 Dec;62(12):3607-14. doi: 10.1002/art.27702.

10.

Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response.

Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP.

Ann Rheum Dis. 2008 Jul;67(7):917-25. Epub 2007 Oct 26.

11.

Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.

Hyrich KL, Watson KD, Silman AJ, Symmons DP; British Society for Rheumatology Biologics Register.

Rheumatology (Oxford). 2006 Dec;45(12):1558-65. Epub 2006 May 16.

12.

Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation.

Teng YK, Levarht EW, Toes RE, Huizinga TW, van Laar JM.

Ann Rheum Dis. 2009 Jun;68(6):1011-6. doi: 10.1136/ard.2008.092791. Epub 2008 Jul 22.

PMID:
18647852
13.

The gene expression profile in the synovium as a predictor of the clinical response to infliximab treatment in rheumatoid arthritis.

Lindberg J, Wijbrandts CA, van Baarsen LG, Nader G, Klareskog L, Catrina A, Thurlings R, Vervoordeldonk M, Lundeberg J, Tak PP.

PLoS One. 2010 Jun 25;5(6):e11310. doi: 10.1371/journal.pone.0011310.

14.

The role of the FcGRIIIa polymorphism in modifying the association between treatment and outcome in patients with rheumatoid arthritis treated with rituximab versus TNF-α antagonist therapies.

Sarsour K, Greenberg J, Johnston JA, Nelson DR, O'Brien LA, Oddoux C, Ostrer H, Pearlman A, Reed G.

Clin Exp Rheumatol. 2013 Mar-Apr;31(2):189-94. Epub 2012 Dec 13.

PMID:
23294992
15.

Effectiveness of rituximab in patients with rheumatoid arthritis: observational study from the British Society for Rheumatology Biologics Register.

Soliman MM, Hyrich KL, Lunt M, Watson KD, Symmons DP, Ashcroft DM; British Society for Rheumatology Biologics Register.

J Rheumatol. 2012 Feb;39(2):240-6. doi: 10.3899/jrheum.110610. Epub 2011 Dec 15.

16.

Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.

Sekiguchi N, Kawauchi S, Furuya T, Inaba N, Matsuda K, Ando S, Ogasawara M, Aburatani H, Kameda H, Amano K, Abe T, Ito S, Takeuchi T.

Rheumatology (Oxford). 2008 Jun;47(6):780-8. doi: 10.1093/rheumatology/ken083. Epub 2008 Apr 3.

17.

Rituximab treatment induces the expression of genes involved in healing processes in the rheumatoid arthritis synovium.

Gutierrez-Roelens I, Galant C, Theate I, Lories RJ, Durez P, Nzeusseu-Toukap A, Van den Eynde B, Houssiau FA, Lauwerys BR.

Arthritis Rheum. 2011 May;63(5):1246-54. doi: 10.1002/art.30292.

18.

The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study.

Klaasen R, Thurlings RM, Wijbrandts CA, van Kuijk AW, Baeten D, Gerlag DM, Tak PP.

Arthritis Rheum. 2009 Nov;60(11):3217-24. doi: 10.1002/art.24913.

19.

Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs.

Narvaez J, Díaz-Torné C, Ruiz JM, Hernandez MV, Torrente-Segarra V, Ros S, Rodriguez de la Serna A, Díaz-López C, Sanmartí R, Nolla JM.

Clin Exp Rheumatol. 2011 Nov-Dec;29(6):991-7. Epub 2011 Dec 22.

PMID:
22133052
20.

Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients.

Lindberg J, af Klint E, Catrina AI, Nilsson P, Klareskog L, Ulfgren AK, Lundeberg J.

Arthritis Res Ther. 2006;8(6):R179.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk